2024. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Improvement in Scalp-Related Quality of Life and Symptoms in the Phase 3b/4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled PSORIATYK SCALP Trial. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s425. DOI:https://doi.org/10.25251/skin.8.supp.425.